0 CHECKOUT

EpiCast Report: Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2023

  • ID: 3431860
  • September 2015
  • Region: Global
  • 65 pages
  • GlobalData
1 of 3
Total Prevalent Cases of HIV in the Eight Major Global Markets is Forecast to Increase to 4,126,502 by 2023

The human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, and the infected person becomes more susceptible to other infections. It can take as long as two to 10 years for a person infected with HIV to develop acquired immunodeficiency syndrome (AIDS), which is the most advanced stage of HIV; however, treatment with antiretroviral drugs can slow the process even further.

In 2013, there were 3,394,507 total prevalent cases of HIV in the 8MM, with 1,218,323 cases in the US and 641,500 in the 5EU markets combined. Japan had 18,428 20-year diagnosed prevalent cases of HIV in 2013. Epidemiologists forecast that the total prevalent cases of HIV in the 8MM will increase to 4,126,502 in the 8MM by 2023. Additionally, epidemiologists forecast that the 20-year diagnosed prevalent cases of HIV in Japan will increase to 27,264 cases by 2023.

For the purposes of this report, epidemiologists reviewed national and international HIV and AIDS databases and used reliable data to build this forecast. The total prevalent cases of HIV READ MORE >

Note: Product cover images may vary from those shown
2 of 3

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 US
3.3.2 5EU
3.3.3 Brazil, China, and Japan
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for HIV in the 8MM (2013-2023)
3.5.1 Total Prevalent Cases of HIV
3.5.2 Age-Specific Total Prevalent Cases of HIV
3.5.3 Sex-Specific Total Prevalent Cases of HIV
3.5.4 Age-Standardized Total Prevalence of HIV
3.5.5 HIV Cases Treated with ART
3.5.6 Cases of HIV in Pregnant Women
3.6 Epidemiological Forecast for HIV in Japan (2013-2023)
3.6.1 20-Year Diagnosed Prevalent Cases of HIV
3.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV
3.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV
3.6.4 Age-Standardized 20-Year Diagnosed Prevalence of HIV
3.6.5 HIV Cases Treated with ART
3.6.6 Cases of HIV in Pregnant Women
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 Physicians and Specialists Included in this Study
4.3 Primary Research - Prescriber Survey
4.4 About the Authors
4.4.1 Epidemiologists
4.4.2 Reviewers
4.4.3 Global Director of Therapy Analysis and Epidemiology
4.4.4 Global Head of Healthcare
4.5 About Us
4.6 About EpiCast
4.7 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for HIV
Table 2: US, Total Prevalence of HIV in Men and Women (%), Ages =13 Years, 2006-2010
Table 3: 5EU, Total Prevalence of HIV in Men (%), All Ages, Selected Years, 2001-2013
Table 4: 5EU, Total Prevalence of HIV in Women (%), All Ages, Selected Years, 2001-2013
Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of HIV
Table 6: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan
Table 7: 9MM, Sources Used to Forecast the ART Treatment Rate Among the Total Prevalent Cases of HIV
Table 8: 9MM, Sources Used to Forecast the Prevalent Cases of HIV-Positive Pregnant Women
Table 9: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023
Table 10: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N (Row %), 2013
Table 11: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N (Row %), 2013
Table 12: 8MM, HIV Cases Treated with ART, N (Col %), All Ages, Both Sexes, Selected Years 2013-2023
Table 13: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013-2023
Table 14: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N (Row %), 2013
Table 15: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013
Table 16: Japan, HIV Cases Treated with ART, All Ages, Both Sexes, N, Selected Years 2013-2023
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

1.2 List of Figures

Figure 1: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023
Figure 2: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N, 2013
Figure 3: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N, 2013
Figure 4: 8MM, Age-Standardized Total Prevalence of HIV, All Ages, N, 2013
Figure 5: 8MM, Cases of HIV in Pregnant Women Among the Total Prevalent Cases of HIV in Women, N, 2013 and 2023
Figure 6: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, 2013-2023
Figure 7: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N, 2013
Figure 8: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013
Figure 9: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV, All Ages, N, 2013
Figure 10:Japan, Cases of HIV in Pregnant Women Among Diagnosed Prevalent Cases of HIV in Women, N, 2013 and 2023

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.